EGEN, Inc. Report issue

For profit Phase 2
Founded: Huntsville AL United States (2002)
Status: Acquired by Celsion (2014)

Organization Overview

First Clinical Trial
2005
NCT00137865
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

egen-001 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Ovarian Neoplasms (Phase 1)

Peritoneal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1